The cell biology technology developer, based on UC Berkeley research, took its total funding to almost $220m in a Nikon-led round that included fellow strategic backer Varian.

Karolinska Institute spinout Palette Life Sciences will add three medical products based on Nestlé’s intellectual property to its existing program targeting pain suffered during gynaecological procedures.

Mercia Technologies has returned to back Locate Bio's pursuit of orthopaedic therapies based on research at University of Nottingham.

The cell biology technology developer took its total funding to almost $220m in a Nikon-led round that included fellow strategic backer Varian.

Legend Holdings, Eli Lilly, Ping An, China Life and Taikang Insurance are in line for exits as Innovent Biologics gears up for an initial public offering sized at $400m to $500m.

Taiho Ventures, launched two years ago with $50m in capital, has had its reserves expanded by a further $250m as Taiho Pharmaceuticals looks to enhance its open innovation work.

The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.

University of Bristol Enterprise Fund II has backed antibiotic diagnostics developer Vitamica, which spun out of the university’s school of physics in January 2018.

University of Kentucky will lead a consortium of academic institutions participating in a US government-funded commercialisation hub intended to accelerate biomedical research.

University of Notre Dame and Indiana University have both backed a $9m seed fund aimed at supporting local businesses in life sciences, health IT and agricultural biosciences.